Tim-3 Antibodies Selective Ligand Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-Tim-3 antibodies fail to selectively block interactions between Tim-3 and its ligands, leading to immune exhaustion and inadequate anti-tumor responses, necessitating the development of antibodies that specifically inhibit Tim-3's interactions with galectin-9 and phosphatidylserine while preserving interactions with CEACAM1 to enhance T-cell responses against tumors.
Innovation Solution
Development of antibodies that bind to specific epitopes on human Tim-3, blocking interactions with galectin-9 and phosphatidylserine without interfering with CEACAM1, thereby enhancing T-cell infiltration and persistence in tumor microenvironments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Tim-3 antibodies are used to block Tim-3 ligand interactions, then anti-tumor immune response is enhanced, but selectivity in blocking specific ligand interactions is insufficient
Solution Approach 1:
The patent applies local quality by designing antibodies with specific variable region sequences (HCDR1-HCDR3 and LCDR1-LCDR3) that are tailored to recognize and block only specific Tim-3 ligand interactions. The precise amino acid sequences in the complementarity-determining regions create localized binding specificity, allowing the antibody to differentiate between galectin-9/phosphatidylserine interactions versus CEACAM1 interactions, thereby achieving selective inhibition of harmful ligand bindings while preserving beneficial ones.
2Reliability
If Tim-3 interactions with all ligands are blocked, then immune exhaustion is reduced, but interactions with beneficial ligands like CEACAM1 are also inhibited
Solution Approach 1:
The patent converts the potential harm of non-selective Tim-3 blocking into a benefit by designing an antibody that exploits the structural differences in ligand-binding epitopes. The antibody specifically targets the galectin-9 and phosphatidylserine binding sites on Tim-3, converting the broad blocking capability into selective inhibition. This allows the antibody to eliminate harmful interactions (with galectin-9 and phosphatidylserine) while preserving beneficial interactions (with CEACAM1), effectively using the diversity of ligand-binding sites to achieve differential blocking.
3Productivity
If existing anti-Tim-3 antibodies are used, then T-cell responses are enhanced, but differential blocking of ligand interactions is not achieved
Solution Approach 1:
The patent applies parameter changes by precisely engineering the amino acid sequences of the antibody's complementarity-determining regions. The specific sequences in HCDR1-HCDR3 and LCDR1-LCDR3 represent optimized parameters that confer selective binding affinity. By adjusting these sequence parameters, the antibody achieves differential blocking capability - maintaining high affinity for galectin-9 and phosphatidylserine while having reduced affinity or no affinity for CEACAM1, thus enabling selective ligand interaction blocking while preserving T-cell response enhancement.
Data Source
AI summary
The present disclosure relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.